Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 506-513

  Finke, Jürgen ^a   Schmoor, Claudia ^a   Lang, Helmut ^a   Potthoff, Karin ^a   Bertz, Hartmut ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; METHOTREXATE; T LYMPHOCYTE GLOBULIN ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW DEPRESSION; CANCER REGRESSION; CANCER RELAPSE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ALLOTRANSPLANTATION; ANIMAL; BLOOD DISEASE; CANCER STAGING; CLINICAL TRIAL; FEMALE; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RABBIT; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASM STAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RABBITS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0037318188     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.129     Document Type: Article

References (28)

1. Sierra J, Storer B, Hansen JA, et al: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89:4226-4235, 1997
2. Hansen JA, Petersdorf E, Martin PJ, et al: Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 157:141-151, 1997
3. Devergie A, Apperley JF, Labopin M, et al: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia: Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11-19, 1997
4. Madrigal JA, Scott I, Arguello R, et al: Factors influencing the outcome of bone marrow transplants using unrelated donors. Immunol Rev 157:153-166, 1997
5. Gratwohl A, Hermans J, Goldman JM, et al: Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087-1092, 1998
6. Kollman C, Howe CW, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 98:2043-2051, 2001
7. Davies SM, Shu XO, Blazar BR, et al: Unrelated donor bone marrow transplantation: Influence of HLA A and B incompatibility on outcome. Blood 86:1636-1642, 1995
8. McGlave PB, Shu XO, Wen W, et al: Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95:2219-2225, 2000
9. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998
10. Champlin R, Schmitz N, Horowitz MM, et al: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95:3702-3709, 2000
11. Finke J, Bertz H, Schmoor C, et al: Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T cell globulin. Br J Haematol 111:303-313, 2000
12. Wäsch R, Reisser S, Hahn J, et al: Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 26:243-250, 2000
13. Chao NJ, Schmidt GM, Niland JC, et al: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host-disease. N Engl J Med 329:1225-1229, 1993
14. Marubini E, Valsecchi MG: Analyzing Survival Data From Clinical Trials and Observational Studies. Chichester, United Kingdom, John Wiley, 1995
15. Petersdorf EW, Longton GM, Anasetti C, et al: The significance of HLA-DRBI matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86:1606-1613, 1995
16. Petersdorf EW, Mickelson EM, Anasetti C, et al: Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 11:521-526, 1999
17. Sasazuki T, Juji T, Morishima Y, et al: Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339:1177-1185, 1998
18. Petersdorf EW, Kollman C, Hurley CK, et al: Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: The US National Marrow Donor Program Experience. Blood 98:2922-2929, 2001
19. Scott I, O'Shea J, Bunce M, et al: Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection. Blood 92:4864-4871, 1998
20. Nash RA, Antin JH, Karanes C, et al: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062-2068, 2000
21. Soiffer RJ, Weller E, Alyea EP, et al: CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 19:1152-1159, 2001
22. Kroger N, Zabelina T, Krüger W, et al: Graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 80:209-215, 2001
23. Ringden O, Remberger M, Carlens S, et al: Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 66:620-625, 1998
24. Kalhs P, Brugger S, Reiter E, et al: Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. Bone Marrow Transplant 23:753-758, 1999
25. Nademanee A, Schmidt GM, Parker P, et al: The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86:1228-1234, 1995
26. Berger C, Bertz H, Schmoor C, et al: Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome after allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 23:983-990, 1999
27. Bacigalupo A, Lamparelli T, Bruzzi P, et al: Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942-2947, 2001
28. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000